Cyclic peptide immunomodulators
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
1. A compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein:
A is selected from a bond,
wherein:
denotes the point of attachment to the carbonyl group and denotes the point of attachment to the nitrogen atom;
z is 0, 1, or 2;
w is 1 or 2;
n is 0 or 1;
m is 1 or 2;
m′ is 0 or 1;
p is 0, 1, or 2;
R x is selected from hydrogen, amino, hydroxy, and methyl;
R 14 and R 15 are independently selected from hydrogen and methyl; and
R z is selected from hydrogen and —C(O)NHR 16 ; wherein R 16 is selected from hydrogen, —CHR 17 C(O)NH 2 , —CHR 17 C(O)NHCHR 18 C(O)NH 2 , and —CHR 17 C(O)NHCHR 18 C(O)NHCH 2 C(O)NH 2 ; wherein R 17 is selected from hydrogen and —CH 2 OH and wherein R 18 is selected from hydrogen and methyl;
R v is hydrogen or a natural amino acid side chain;
R c , R f , R h , R i , and R m are hydrogen;
R L is methyl;
R n is hydrogen or methyl or R v and R n form a pyrrolidine ring;
R a , R j , and R k , are each independently selected from hydrogen and methyl;
R 1 , R 3 , R 6 , R 8 , R 9 , R 10 , and R 13 are independently selected from a natural amino acid side chain and an unnatural amino acid side chain;
Q is a five- to twelve-membered carbon chain optionally containing one carbon-carbon double bond or a phenoxy group;
R 2 , R 4 , R 5 ,and R 7 are independently selected from a natural amino acid side chain and an unnatural amino acid side chain, or form a ring with a geminal R group as described below;
R b is methyl or, R b and R 2 , together with the atoms to which they are attached, form a ring selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, and hydroxy;
R d is hydrogen or methyl, or, R d and R 4 , together with the atoms to which they are attached, can form a ring selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, hydroxy, and phenyl;
R e is hydrogen or methyl, or, R e and R 5 , together with the atoms to which they are attached, can form a ring selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, and hydroxy; and
R g is hydrogen or methyl or R g and R 7 , together with the atoms to which they are attached, can form a ring selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one to four groups independently selected from amino, benzyl optionally substituted with a halo group, benzyloxy, cyano, cyclohexyl, methyl, halo, hydroxy, isoquinolinyloxy optionally substituted with a methoxy group, quinolinyloxy optionally substituted with a halo group, and tetrazolyl; and wherein the pyrrolidine and the piperidine ring are optionally fused to a cyclohexyl, phenyl, or indole group.
2. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is
3. A compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein
z is 0;
w is 1;
R 14 and R 15 are hydrogen; and
R z is —C(O)NHR 16 ; wherein R 16 is —CHR 17 C(O)NH 2 .
4. A compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein
R 1 is benzyl optionally substituted with hydroxy;
R 2 is methyl or, together with R b , forms a ring selected from piperidine, piperazine, and morpholine;
R 3 is selected from —CH 2 C(O)NH 2 and —CH 2 CO 2 H;
R 4 , together with R d , forms a pyrrolidine ring;
R 5 is selected from —CH 2 (imidazolyl) and —CH 2 NH 2 ;
R 6 is selected from isobutyl, —(CH 2 ) 2 CO 2 H, and —(CH 2 ) 2 CONH 2 ;
R 7 is hyrogen or, together with R g , forms a pyrrolidine ring optionally substituted with hydroxy;
R 8 is —(CH 2 )indolyl;
R 9 is selected from —CH 2 OH and —(CH 2 ) 2 NH 2 ; and
R 19 is selected from —(CH 2 )indolyl and —(CH 2 )benzothienyl, each optionally substituted with —CH 2 CO 2 H.
5. A method of enhancing, stimulating, and/or increasing the immune response in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a therapeutically acceptable salt thereof.
6. The method of claim 5 further comprising administering an additional agent prior to, after, or simultaneously with the compound of claim 1 or a therapeutically acceptable salt thereof.
7. The method of claim 6 wherein the additional agent is an antimicrobial agent, an antiviral agent, a cytotoxic agent, and/or an immune response modifier.
8. The method of claim 6 wherein the additional agent is an HDAC inhibitor.
9. The method of claim 6 wherein the additional agent is a TLR7 and/or TLR8 agonist.
10. A method of inhibiting growth, proliferation, or metastasis of cancer cells in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount a compound of claim 1 or a therapeutically acceptable salt thereof.
11. The method of claim 10 wherein the cancer is selected from melanoma, renal cell carcinoma, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, colorectal cancer, castration-resistant prostate cancer, ovarian cancer, gastric cancer, hepatocellular carcinoma, pancreatic carcinoma, squamous cell carcinoma of the head and neck, carcinomas of the esophagus, gastrointestinal tract and breast, and hematological malignancies.
12. A method of treating an infectious disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a therapeutically acceptable salt thereof, wherein treating refers to inhibiting the disease or relieving the disease.
13. The method of claim 12 wherein the infectious disease is caused by a virus.
14. The method of claim 13 wherein the virus is selected from HIV, Hepatitis A, Hepatitis B, Hepatitis C, herpes viruses, and influenza.
15. A method of treating septic shock in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a therapeutically acceptable salt thereof, wherein treating refers to inhibiting the disease or relieving the disease.
16. A method blocking the interaction of PD-L1 with PD-1 and/or CD80 in a subject, said method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a therapeutically acceptable salt thereof.